Phaseline

Targets › NOROVIRUS

NOROVIRUS: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on NOROVIRUS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Anhui Zhifei Longcom Biologic Pharmacyquadrivalent recombinant norovirus vaccine (Pichia pastoris)
Recombinant norovirus VP1 capsid proteins (GI.1, GII.3, GII.4, GII.17)
NOROVIRUSPhase 3Acute Gastroenteropathy Due to NorovirusMar 2027

Conditions

Acute Gastroenteropathy Due to Norovirus (1)

Modalities

other (1)

Companies

Anhui Zhifei Longcom Biologic Pharmacy (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.